Top Page
Immuron Limited
(Frankfurt:IMC)
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Immuron Limited Business Overview & Revenue Model
Immuron Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.29M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 4.77M | 4.77M | 3.34M | 1.31M | 523.50K | 94.70K |
| EBITDA | -5.31M | -5.31M | -6.19M | -3.80M | -3.08M | -8.33M |
| Net Income | -5.22M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 10.13M | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 117.13K | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 8.07M | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -6.14M | -5.56M | -2.50M | -3.14M | -4.09M |
| Operating Cash Flow | -6.14M | -6.14M | -5.56M | -2.49M | -3.13M | -4.08M |
| Investing Cash Flow | -2.98M | -2.90M | 327.56K | -2.74M | 11.74K | 2.57K |
| Financing Cash Flow | 203.03K | 199.75K | 829.00 | -35.02K | -36.26K | 26.49M |
Immuron Limited Technical Analysis
Immuron Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$46.56M | -11.11 | -16.65% | ― | ― | -672.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$22.04M | ― | -143.71% | ― | 306.88% | ― | |
41 Neutral | AU$18.89M | ― | -49.96% | ― | 48.63% | 25.66% | |
37 Underperform | AU$6.62M | ― | -628.72% | ― | ― | 31.87% | |
36 Underperform | AU$26.89M | -5.51 | -157.93% | ― | ― | -36.89% | |
27 Underperform | AU$3.46M | ― | -205.70% | ― | ― | 1.03% |
Immuron Limited Corporate Events
Immuron Limited has received FDA approval for its Investigational New Drug (IND) application for IMM-529, allowing the company to proceed with a Phase 2 clinical trial targeting Clostridioides difficile infection (CDI). The trial aims to evaluate the safety and efficacy of IMM-529 as an adjunctive therapy with standard care, potentially positioning it as an early treatment option for CDI, a significant healthcare-associated infection. The development of IMM-529 addresses the urgent need for new therapeutics to reduce antibiotic reliance, with projections indicating a potential annual revenue of $400 million if successful.
Immuron Limited has provided an update on its clinical trials for Travelan® and IMM-529. The company’s IND application for IMM-529, aimed at preventing or treating Clostridioides difficile infection, is under review by the FDA, with minor updates submitted following a request for additional information. Additionally, the release of topline data from the Travelan® P2TD study has been delayed due to a U.S. government shutdown, impacting the company’s dosing strategy for an upcoming FDA meeting. The outcomes of these trials are crucial for Immuron’s strategic planning and could influence its market positioning and stakeholder interests.
Immuron Limited announced the cessation of 500,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 26, 2025. This announcement may impact the company’s capital structure but does not indicate immediate changes in its operational strategies or market positioning.
Immuron Limited has launched PROIBS®, a new product aimed at treating symptoms of Irritable Bowel Syndrome (IBS) in the Australian market. This launch is strategically timed for the festive season when IBS symptoms are more prevalent. PROIBS® is a certified medical device containing AVH200®, derived from Aloe barbadensis, and is designed for long-term use without known medication interactions. The product has shown promising results in a usability study, with a high percentage of users reporting improvements. This addition to Immuron’s product line, which includes the successful Travelan® brand, is expected to strengthen its position in the digestive health market, which is projected to grow in Australia.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant benefits to stakeholders.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the AusBiotech Invest 2025 conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant implications for stakeholders, particularly in the areas of travelers’ health and gastrointestinal treatments.
Immuron Limited has announced the issuance of 1,133,840 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirms compliance with relevant provisions of the Corporations Act and states there is no excluded information requiring disclosure, indicating a transparent operational stance.
Immuron Limited has announced the quotation of 1,133,840 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 20, 2025. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, impacting its operations and positioning within the biotechnology sector.
Immuron Limited reported a 34% year-over-year increase in global sales for Q1 FY26, driven by strong performance in Australia and the USA. The company’s flagship product, Travelan®, an immune supplement targeting gastrointestinal pathogens, saw significant growth due to enhanced marketing efforts and increased travel activity. While Canadian sales were down, Immuron anticipates recovery through upcoming consumer promotions and increased brand awareness.
Immuron Limited has announced its 2025 Annual General Meeting, scheduled for November 11, 2025, in Melbourne. The meeting will address several key resolutions, including the adoption of the Remuneration Report and the re-election of two directors, Prof Ravi Savarirayan and Mr Paul Brennan. Shareholders can attend in person or virtually, although virtual attendees will not be able to vote. This meeting is significant for stakeholders as it will determine leadership continuity and compensation policies, impacting the company’s strategic direction and governance.
Immuron Limited has submitted an Investigational New Drug (IND) application to the FDA for the clinical development of IMM-529, aimed at treating and preventing Clostridioides difficile infection (CDI). The company plans to initiate a Phase 2 clinical trial in 2026, targeting both first episode and recurrent CDI patients. IMM-529’s oral administration and its potential to accelerate the clearance of CDI infection make it a promising candidate in addressing the urgent need for new therapeutics, especially given the rising incidence of antibiotic-resistant infections. With a projected annual revenue potential of approximately US$400 million, IMM-529 could significantly impact the treatment landscape for CDI, offering a novel approach that combines standard antibiotics with targeted antibodies to restore healthy gut microbiota.
Immuron Limited has filed an ATM supplementary prospectus with the U.S. Securities and Exchange Commission to extend its At-the-market (ATM) funding facility with H.C. Wainwright & Co., LLC. This strategic move allows Immuron to raise approximately US$2,847,954, providing the company with financial flexibility and an efficient mechanism to raise additional equity capital in response to operational needs and market opportunities.
Immuron Limited announced several key updates, including the anticipated topline results of the Travelan® clinical study and the submission of an IND application for IMM-529 to the FDA. The company is on track for the commercial launch of ProIBS® in Australia by Q4 2025, with a full launch expected in Q1 2026. Immuron’s progress in these areas highlights its strategic focus on expanding its product offerings and strengthening its market position in the treatment of gastrointestinal and infectious diseases.
Immuron Limited has released its corporate governance statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rules. The statement, available on their website, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. This disclosure is crucial for stakeholders as it provides transparency regarding the company’s governance practices and ensures accountability in its management and oversight processes.
Immuron Limited has released its Annual Report for 2025, highlighting its commitment to corporate governance and transparency. The report includes a review of operations, consolidated financial statements, and an independent auditor’s report, which collectively provide insights into the company’s financial health and strategic direction.
Immuron Limited announced that CEO Steven Lydeamore will present at the Coffee Microcaps VIP Conference, highlighting the company’s ongoing efforts in the biopharmaceutical sector. This presentation underscores Immuron’s commitment to advancing its product offerings, such as Travelan® and IMM-529, which aim to address significant health issues like travelers’ diarrhea and Clostridioides difficile infections, potentially strengthening its position in the market and benefiting stakeholders.
Immuron Limited has released its FY2025 results, highlighting the company’s ongoing efforts in developing and commercializing its biotechnology products. The announcement underscores the potential risks and uncertainties associated with their operations, which may impact future results. The results are subject to audit review, reflecting the company’s commitment to transparency and regulatory compliance.
Immuron Limited reported a 48.6% increase in revenue to $7.29 million for the year ended June 30, 2025, driven by strong sales of its Travelan product in Australia and North America. Despite a reduction in losses by 24.3% to $5.25 million, the company’s cash position decreased significantly to $2.83 million from the previous year. The company anticipates continued revenue growth from Travelan, although no dividends were declared for the year.
Immuron Limited has partnered with InvestorHub to enhance its communication with investors and stakeholders through a new interactive investor hub. This initiative aligns with the company’s strategy to better engage its investment community, especially as it approaches significant milestones such as the FDA submission for IMM-529 and the release of clinical trial results for Travelan®. The partnership is expected to strengthen Immuron’s market presence and improve investor relations by providing a centralized platform for content and updates.
Immuron Limited announced the issuance of 2,147,154 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize its workforce, potentially impacting its operational efficiency and market positioning.